共 384 条
[1]
Altomonte M(2003)Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene 22 6564-6569
[2]
Fonsatti E(2006)Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients Cancer Res 66 6405-6411
[3]
Visintin A(2008)Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations Cancer Immunol Immunother 57 1727-1733
[4]
Maio M(1998)Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides Tissue Antigens 52 520-529
[5]
Anichini A(2000)CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro Cancer Immunol Immunother 48 621-626
[6]
Mortarini R(1995)Biological implications of HLA-DR expression in tumours Scand J Immunol 41 398-406
[7]
Nonaka D(1996)High frequency of altered HLA class I phenotypes in invasive breast carcinomas Hum Immunol 50 127-134
[8]
Molla A(2007)HLA class I expression in metastatic melanoma correlates with tumour development during autologous vaccination Cancer Immunol Immunother 56 709-717
[9]
Vegetti C(2006)Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas Clin Cancer Res 12 4163-4170
[10]
Montaldi E(2006)Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells J Immunol 177 3100-3107